Business
CAMP4 Reports First Quarter 2025 Financial Results and Corporate Highlights
Phase 1 clinical trial of CMP-CPS-001 in Urea Cycle Disorders (UCDs) ongoing, with dosing complet...
About this update from Canadian Goldcamps Corp
[{"type":"text","content":"CAMP4 Reports First Quarter 2025 Financial Results and Corporate Highlights\n\n\n\n\n Phase 1 clinical trial of CMP-CPS-001 in Urea Cycle Disorders (UCDs) ongoing, with dosing completed in multiple ascending dose (MAD) cohort 3; safety, pharmacokinetic, and pharmacodynamic data expected Q4 2025\n \n\n CTA successfully submitted in Europe for Phase 1b clinical trial in female OTC heterozygotes\n \n\n Nominated development candidate, CMP-SYNGAP-01, to address SYNGAP1-related disorders; GLP toxicology studies expected to be initiated in 2025\n \n\n American Society of Cell and Gene Therapy (ASGCT) oral presentations to highlight meaningful increase in SYNGAP1 protein, driven by lead ASO candidate, CMP-SYNGAP-01, in non-human primates (NHP) and review interim SAD data from the Phase 1 trial of CMP-CPS-001 in healthy volunteers\n \n\n Expect to receive milestone payment from Fulcrum Therapeutics under the license agreement signed July 2023 for our Diamond-Blackfan Anemia (DBA) program\n \n\n\n\n CAMBRIDGE, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced financial results for the first quarter ended March 31, 2025, and provided a corporate update.\n \n\n “We are very pleased with the strong execution during the first quarter of 2025,” said Josh Mandel-Brehm, President and Chief Executive Officer of CAMP4. “We made important advances in our clinical study of CMP-CPS-001 for the treatment of UCDs, submitting a CTA in Europe for a Phase 1b expansion to enroll female participants who are heterozygous for a mutation of the OTC gene, pending regulatory clearance. We remain on track to release safety, pharmacokinetic, and pharmacodynamic data from the MAD portion of this Phase 1 study in Q4 2025. In addition, we learned that we are eligible to receive a milestone payment from Fulcrum Therapeutics under the license agreement signed in July 2023, under which Fulcrum was granted a worldwide exclusive license to rights under our DBA program. This achievement further validates our ability to create meaningful valu...